Literature DB >> 30846496

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Chloé B Steen1,2, Ellen Leich3, June H Myklebust2,4, Sandra Lockmer5, Jillian F Wise2,4, Björn E Wahlin5, Bjørn Østenstad6, Knut Liestøl1,7, Eva Kimby5, Andreas Rosenwald3, Erlend B Smeland2,4, Harald Holte4,6, Ole Christian Lingjærde8,4,9, Marianne Brodtkorb10,4,6.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30846496      PMCID： PMC6886427          DOI： 10.3324/haematol.2018.209080

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.

Authors:  Andrew J Davies; Andreas Rosenwald; George Wright; Abigail Lee; Kim W Last; Dennis D Weisenburger; Wing C Chan; Jan Delabie; Rita M Braziel; Elias Campo; Randy D Gascoyne; Elaine S Jaffe; Konrad Muller-Hermelink; German Ott; Maria Calaminici; Andrew J Norton; Lindsey K Goff; Jude Fitzgibbon; Louis M Staudt; T Andrew Lister
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

3.  Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma.

Authors:  Marianne Brodtkorb; Ole Christian Lingjærde; Kanutte Huse; Gunhild Trøen; Marit Hystad; Vera I Hilden; June H Myklebust; Ellen Leich; Andreas Rosenwald; Jan Delabie; Harald Holte; Erlend B Smeland
Journal:  Blood       Date:  2013-12-19       Impact factor: 22.113

4.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Authors:  Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

5.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

6.  Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.

Authors:  Sandra Lockmer; Bjørn Østenstad; Hans Hagberg; Harald Holte; Ann-Sofie Johansson; Björn Engelbrekt Wahlin; Karin Fahl Wader; Chloé Beate Steen; Peter Meyer; Martin Maisenhølder; Karin Ekström Smedby; Peter Brown; Eva Kimby
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544

7.  Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

Authors:  Eva Kimby; Jesper Jurlander; Christian Geisler; Hans Hagberg; Harald Holte; Tuula Lehtinen; Björn Ostenstad; Mads Hansen; Anders Osterborg; Ola Lindén; Christer Sundström
Journal:  Leuk Lymphoma       Date:  2008-01

8.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Authors:  Alessandro Pastore; Vindi Jurinovic; Robert Kridel; Eva Hoster; Annette M Staiger; Monika Szczepanowski; Christiane Pott; Nadja Kopp; Mark Murakami; Heike Horn; Ellen Leich; Alden A Moccia; Anja Mottok; Ashwini Sunkavalli; Paul Van Hummelen; Matthew Ducar; Daisuke Ennishi; Hennady P Shulha; Christoffer Hother; Joseph M Connors; Laurie H Sehn; Martin Dreyling; Donna Neuberg; Peter Möller; Alfred C Feller; Martin L Hansmann; Harald Stein; Andreas Rosenwald; German Ott; Wolfram Klapper; Michael Unterhalt; Wolfgang Hiddemann; Randy D Gascoyne; David M Weinstock; Oliver Weigert
Journal:  Lancet Oncol       Date:  2015-08-06       Impact factor: 41.316

9.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Authors:  Brian K Link; Matthew J Maurer; Grzegorz S Nowakowski; Stephen M Ansell; William R Macon; Sergei I Syrbu; Susan L Slager; Carrie A Thompson; David J Inwards; Patrick B Johnston; Joseph P Colgan; Thomas E Witzig; Thomas M Habermann; James R Cerhan
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

10.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

Authors:  Abdulwahab J Al-Tourah; Karamjit K Gill; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Laurie H Sehn; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.